Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy

Abstract To evaluate the long-term outcomes of ranibizumab (RBZ) vs. aflibercept (AFL) in treatment-naïve eyes with typical neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). This multicenter, retrospective, matched-cohort analysis was conducted on data ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ki Won Jin, Jae Hui Kim, Jun Young Park, Sang Jun Park, Kyu Hyung Park, Joo Yong Lee, Se Joon Woo
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6a881a6887af467c83775ff59e555030
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6a881a6887af467c83775ff59e555030
record_format	dspace
spelling	oai:doaj.org-article:6a881a6887af467c83775ff59e5550302021-12-02T16:14:03ZLong-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy10.1038/s41598-021-93899-x2045-2322https://doaj.org/article/6a881a6887af467c83775ff59e5550302021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93899-xhttps://doaj.org/toc/2045-2322Abstract To evaluate the long-term outcomes of ranibizumab (RBZ) vs. aflibercept (AFL) in treatment-naïve eyes with typical neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). This multicenter, retrospective, matched-cohort analysis was conducted on data up to 4 years of follow-ups. The primary outcome was the visual acuity (VA) change from baseline. The secondary outcomes included the number of injections, proportion of eyes without a yearly injection, and the number of eyes with treatment switching. Subgroup analyses were performed for typical nAMD and PCV. Typical nAMD was defined as nAMD other than PCV. We included VA-matched 215 eyes of 209 patients (131 and 84 eyes with RBZ and AFL, respectively). The crude mean VA changes from baseline were + 6.7 vs. + 2.6, + 2.1 vs. − 0.4, − 1.3 vs. − 1.8, and − 2.2 vs. − 5.0 letters in the RBZ and AFL groups, at 1, 2, 3, and 4 years, respectively (p > 0.05). The adjusted predicted VA by linear mixed model, proportion of eyes stratified by VA, and the survival curve for significant vision loss were comparable during the 4-year follow-up (p > 0.05). The mean number of injections were similar between the RBZ and AFL groups (2.9 vs. 3.0, respectively, p = 0.692). The subgroup analysis for typical nAMD and PCV showed similar results between the groups. The visual outcomes did not differ between RBZ and AFL during 4 years with comparable numbers of injections. Our study reflects the long-term, real-world clinical practice and treatment pattern of two treatments for typical nAMD and PCV.Ki Won JinJae Hui KimJun Young ParkSang Jun ParkKyu Hyung ParkJoo Yong LeeSe Joon WooNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ki Won Jin Jae Hui Kim Jun Young Park Sang Jun Park Kyu Hyung Park Joo Yong Lee Se Joon Woo Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
description	Abstract To evaluate the long-term outcomes of ranibizumab (RBZ) vs. aflibercept (AFL) in treatment-naïve eyes with typical neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). This multicenter, retrospective, matched-cohort analysis was conducted on data up to 4 years of follow-ups. The primary outcome was the visual acuity (VA) change from baseline. The secondary outcomes included the number of injections, proportion of eyes without a yearly injection, and the number of eyes with treatment switching. Subgroup analyses were performed for typical nAMD and PCV. Typical nAMD was defined as nAMD other than PCV. We included VA-matched 215 eyes of 209 patients (131 and 84 eyes with RBZ and AFL, respectively). The crude mean VA changes from baseline were + 6.7 vs. + 2.6, + 2.1 vs. − 0.4, − 1.3 vs. − 1.8, and − 2.2 vs. − 5.0 letters in the RBZ and AFL groups, at 1, 2, 3, and 4 years, respectively (p > 0.05). The adjusted predicted VA by linear mixed model, proportion of eyes stratified by VA, and the survival curve for significant vision loss were comparable during the 4-year follow-up (p > 0.05). The mean number of injections were similar between the RBZ and AFL groups (2.9 vs. 3.0, respectively, p = 0.692). The subgroup analysis for typical nAMD and PCV showed similar results between the groups. The visual outcomes did not differ between RBZ and AFL during 4 years with comparable numbers of injections. Our study reflects the long-term, real-world clinical practice and treatment pattern of two treatments for typical nAMD and PCV.
format	article
author	Ki Won Jin Jae Hui Kim Jun Young Park Sang Jun Park Kyu Hyung Park Joo Yong Lee Se Joon Woo
author_facet	Ki Won Jin Jae Hui Kim Jun Young Park Sang Jun Park Kyu Hyung Park Joo Yong Lee Se Joon Woo
author_sort	Ki Won Jin
title	Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
title_short	Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
title_full	Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
title_fullStr	Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
title_full_unstemmed	Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
title_sort	long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6a881a6887af467c83775ff59e555030
work_keys_str_mv	AT kiwonjin longtermoutcomesofranibizumabvsafliberceptforneovascularagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy AT jaehuikim longtermoutcomesofranibizumabvsafliberceptforneovascularagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy AT junyoungpark longtermoutcomesofranibizumabvsafliberceptforneovascularagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy AT sangjunpark longtermoutcomesofranibizumabvsafliberceptforneovascularagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy AT kyuhyungpark longtermoutcomesofranibizumabvsafliberceptforneovascularagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy AT jooyonglee longtermoutcomesofranibizumabvsafliberceptforneovascularagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy AT sejoonwoo longtermoutcomesofranibizumabvsafliberceptforneovascularagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathy
_version_	1718384354437103616

Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy

Ejemplares similares